Meeting
2015 Genitourinary Cancers Symposium
Dynamic changes of alkaline phosphatase as surrogate for best clinical benefit and overall survival during very early abiraterone therapy compared to PSA-changes in bone metastatic castration resistant prostate cancer.
Authors
Martin Boegemann
Department of Urology, University of Muenster, Muenster, Germany
Martin Boegemann , Phillip Mikah , Okyaz Eminaga , Edwin Herrmann , Philipp Marius Papavassilis , Reemt Hinkelammert , Axel Semjonow , Andres Jan Schrader , Laura-Maria Krabbe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate, Penile, Testicular, and Urethral Cancers, and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 260)
DOI
10.1200/jco.2015.33.7_suppl.260
Abstract #
260
Poster Bd #
D3
Abstract Disclosures
Similar Posters
Poster
2016 Genitourinary Cancers Symposium
![The role of fPSA, [-2]proPSA and the Prostate Health Index for the early prediction of outcome in patients with metastatic castration resistant prostate cancer on therapy with abirateroneacetate.](https://d201v5jt9ylckg.cloudfront.net/172/10995/119695/119695_poster_pv.jpg)
The role of fPSA, [-2]proPSA and the Prostate Health Index for the early prediction of outcome in patients with metastatic castration resistant prostate cancer on therapy with abirateroneacetate.
First Author: Katrin Schlack
Poster
2014 Genitourinary Cancers Symposium
Biochemical response to ketoconazole therapy in post-chemotherapy mCRPC patients.
First Author: M. Andreas Roeder
Poster
2024 ASCO Genitourinary Cancers Symposium
The survival outcomes for men with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination deficiencies (HRD) treated with radium-223: Princess Margaret Cancer Centre (PMCC) experience.
First Author: Esmail M. Al-Ezzi
Poster
2022 ASCO Annual Meeting
Alkaline phosphatase (ALP) decline and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the REASSURE study.
First Author: Nicholas D. James